Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combined With Azacitidine in MDS/MPN
NCT05282719Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Overall Response Rate up to 4 years. Status: unknown.
02
Drugs
venetoclax
03
Conditions
myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT05282719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05282719.